Filtered By:
Condition: Fatty Liver Disease (FLD)
Nutrition: Antidoxidants

This page shows you your search results in order of date.

Order by Relevance | Date

Total 9 results found since Jan 2013.

Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review
Crit Rev Food Sci Nutr. 2022 Jun 16:1-66. doi: 10.1080/10408398.2022.2084600. Online ahead of print.ABSTRACTAge-related diseases are associated with increased morbidity in the past few decades and the cost associated with the treatment of these age-related diseases exerts a substantial impact on social and health care expenditure. Anti-aging strategies aim to mitigate, delay and reverse aging-associated diseases, thereby improving quality of life and reducing the burden of age-related pathologies. The natural dietary antioxidant supplementation offers substantial pharmacological and therapeutic effects against various dise...
Source: Atherosclerosis - June 16, 2022 Category: Cardiology Authors: Phaniendra Alugoju V K D Krishna Swamy Naga Venkata Anusha Anthikapalli Tewin Tencomnao Source Type: research

Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota.
Abstract Nonalcoholic steatohepatitis (NASH), a more advanced form of nonalcoholic fatty liver disease (NAFLD), is associated with increased cardiovascular and liver-related mortality. Stroke-prone spontaneously hypertensive rats (SHRSP5/Dmcr) that are fed a high-fat and high-cholesterol diet develop hepatic lesions that are similar to those observed in human NASH pathology. We investigated the hepatic protective and antioxidant effects of surface-deacetylated chitin nanofibers (SDACNFs) that were administered to SHRSP5/Dmcr rats for 8 weeks. The administration of SDACNFs (80 mg/kg/day) resulted in a significa...
Source: International Journal of Biological Macromolecules - July 18, 2020 Category: Biochemistry Authors: Goto M, Iohara D, Michihara A, Ifuku S, Azuma K, Kadowaki D, Maruyama T, Otagiri M, Hirayama F, Anraku M Tags: Int J Biol Macromol Source Type: research

The Discovery and Development of Liraglutide and Semaglutide
We describe one such approach, albumin binding, and explain how it was applied in the development of the human GLP-1 analog liraglutide once daily and, subsequently, semaglutide once weekly. The pharmacology of these two long-acting GLP-1 analogs, in terms of improving glycemic control, reducing body weight and decreasing cardiovascular (CV) risk, is also reviewed, together with some novel biology. In addition, we describe the importance of accurate target (GLP-1 receptor) tissue expression analysis. Now an established class of agents, GLP-1-based therapies represent a significant advance in the treatment of T2D. All curr...
Source: Frontiers in Endocrinology - April 11, 2019 Category: Endocrinology Source Type: research

Serum vitamin E as a significant prognostic factor in patients with dyslipidemia disorders
ConclusionWe found that vitamin E profile was significantly lower in the dyslipidemia subjects. It is generally suggested that vitamin E monitoring might be used as a useful prognostic and therapeutic agent in dyslipidemia disorder.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - November 14, 2018 Category: Endocrinology Source Type: research

Uric acid and cardiovascular disease
Publication date: September 2018Source: Clinica Chimica Acta, Volume 484Author(s): Gjin NdrepepaAbstractUric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of ...
Source: Clinica Chimica Acta - July 11, 2018 Category: Laboratory Medicine Source Type: research

Uric acid and cardiovascular disease.
Abstract Uric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of them suggested the existence of an association between elevated serum UA level and CVD...
Source: International Journal of Clinical Chemistry - May 24, 2018 Category: Chemistry Authors: Ndrepepa G Tags: Clin Chim Acta Source Type: research

Adiponectin, lipids and atherosclerosis
Purpose of review: Adiponectin is an adipokine with anti-inflammatory, antioxidant, antiatherogenic, pro-angiogenic, vasoprotective and insulin-sensitizing properties. Several factors may influence adiponectin levels, such as genetic polymorphisms, obesity / body fat distribution, diet and exercise as well as cardiovascular risk factors such as sleep deprivation and smoking as well as medications. Adiponectin has been proposed as a potential prognostic biomarker and a therapeutic target in patients with cardiometabolic diseases. Recent findings: This narrative review discusses the associations of adiponectin with obesity-...
Source: Current Opinion in Lipidology - July 14, 2017 Category: Lipidology Tags: HYPERLIPIDAEMIA AND CARDIOVASCULAR DISEASE: Edited by Paul N. Durrington Source Type: research